Role of eating disorders-related polymorphisms in obesity pathophysiology

Nicoletti, Carolina Ferreira; Delfino, Heitor Bernardes Pereira; Ferreira, Flávia Campos; Pinhel, Marcela Augusta de Souza; Nonino, Carla Barbosa

doi:10.1007/s11154-019-09489-w

Cited by 19 publications

(22 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data corroborate with other studies, which also show an association of these polymorphisms with the disease [10,[30][31]. It is known that the presence of these polymorphisms, especially the rs1800497 in DRD2 gene, is associated with reduced dopamine function in the brain [32][33] by about 30 to 40% of the normal value [5]. In addition, they seem to be related to increased BMI and eating disorders in women with bulimia spectrum disorder [34][35], being considered a possible marker for high risk of developing pathological eating behavior [36].…”

Section: Discussionsupporting

confidence: 91%

“…Binge eating episodes are generally associated with aspects such as eating faster than normal, eating more than gastric capacity, eating in large quantities in the absence of physical hunger, and feeling guilty about binge eating, compromising physical and psychosocial health signi cantly [1][2][3]. However, this disorder is not associated with inappropriate compensatory strategies after binge eating, which is why BED is often associated with obesity [1,[4][5]. The prevalence of BED is estimated at 2 to 3.5% and is observed in 5 to 30% of individuals with obesity [2][3].…”

Section: Introductionmentioning

confidence: 99%

“…The etiology of binge eating disorder (BED) is multifactorial, involving genetic, psychological, and sociocultural factors. Among the genetic aspects, we highlight the single nucleotide polymorphisms (SNP), which are examples of genetic modi cations, which can signi cantly in uence the regulation of neural circuits that control the appetite/satiety pathway, as well as the regulation of cerebral reward systems [2,5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

DRD2 and BDNF Polymorphisms Are Associated With Binge Eating Disorder (BED) in Patients With Weight Regain After Bariatric Surgery

Nonino

Barato

Ferreira

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Objectives: Verify the frequency of polymorphisms related to obesity and Binge Eating Disorder (BED) in DRD2 and BDNF genes in patients undergoing bariatric surgery with weight regain above 10% of the weight lost. Methods: Evaluation of 177 individuals undergoing bariatric surgery with weight regain, divided into two groups: Group 1: individuals with BED; Group 2: individuals without BED. The individuals were submitted to anthropometric evaluation, analysis of the presence of BED using a validated questionnaire, and blood collection for genotyping of the polymorphisms, rs6265 (BDNF) and rs1800497 (DRD2). The Kolmogorovi-Smirnov, t-test, chi-square, Mann Whitney, Pearson correlation were used for statistical analysis. Results: CC genotypes for rs1800497 polymorphism, and GG for rs6265 polymorphism were more frequent in patients without the disorder. The presence of at least one T allele (DRD2) and at least one A allele (BDNF) was more frequent in patients with BED. The combination of AA + GA + TT + TC genotypes prevailed in patients with the disorder. Conclusions: The CC (DRD2) and GG (BDNF) genotypes suggest protection for patients against BED, while genotypes that have at least one T allele (DRD2) and one A allele (BDNF) suggest greater risk and appear to act in synergism.Level of evidence: III (evidence obtained from case-control analytic study).

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

DRD2 and BDNF Polymorphisms Are Associated With Binge Eating Disorder (BED) in Patients With Weight Regain After Bariatric Surgery

Nonino

Barato

Ferreira

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, the BS procedure has an influence in reward system leading to a decrease in the preference for palatable foods in post‐BS patients . In this line, disturbances in the reward system are considered currently an essential aspect of eating disorder neurobiology . Thus, this change in the reward circuits after the BS procedure could be involved in the manifestation of eating psychopathology after BS procedure.…”

Section: Discussionmentioning

confidence: 99%

Is weight regain after bariatric surgery associated with psychiatric comorbidity? A systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Summary Bariatric surgery has been recognized as the gold standard treatment for severe obesity. Although postbariatric surgery patients usually achieve and maintain substantial weight loss, a group of individuals may exhibit weight regain. Several factors are proposed to weight regain, including psychiatric comorbidity. The objective of the study is to conduct a systematic review and meta‐analysis of studies investigating the relationship between psychiatric comorbidity and weight regain. A systematic review through PubMed, Web of Science, Cochrane Library, Scopus, and PsycINFO was performed, following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA). After a stepwise selection, 13 articles were included in the qualitative analysis and 5 were included for a meta‐analysis. Women was majority in most of the studies (87.6%), and a bypass procedure was the bariatric intervention most evaluated (66.8%), followed by gastric banding (32.1%) and sleeve (1.1%). Higher rates of postbariatric surgery eating psychopathology were reported in patients with weight regain. However, the association between general psychopathology and weight regain was not consistent across the studies. In the meta‐analysis, the odds of eating psychopathology in the weight regain group was higher compared with the nonweight regain group (OR = 2.2, 95% CI 1.54‐3.15). Postbariatric surgery eating psychopathology seems to play an important role in weight regain.

show abstract

“…Leptin exerts an effect opposite to that of ghrelin and has an anorexigenic effect (appetite inhibitors). Leptin, a hormone mainly produced by adipose tissues, regulates food intake and maintain energy homeostasis . Low levels of leptin are observed in cancer patients with cachexia and cisplatin‐induced anorexia .…”

Section: Introductionmentioning

confidence: 99%

D‐methionine improves cisplatin‐induced anorexia and dyspepsia syndrome by attenuating intestinal tryptophan hydroxylase 1 activity and increasing plasma leptin concentration

Wong

Lin

Liu

et al. 2020

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background:Cisplatin is a widely used antineoplastic drug. However, cisplatin-induced dyspepsia syndromes, including delayed gastric emptying, gastric distension, early satiety, nausea, and vomiting, often force patients to take doses lower than those prescribed or even refuse treatment. D-methionine has an appetite-enhancing effect and alleviates weight loss during cisplatin treatment. Methods:This work established a model of anorexia and dyspepsia symptoms with intraperitoneal injection of cisplatin (5 mg/kg) once a week for three cycles.Presupplementation with or without D-methionine (300 mg/kg) was performed.Orexigenic and anorexigenic hormones (ghrelin, leptin, and glucagon-like peptide-1), tryptophan hydroxylase 1 (TPH1), 5-hydroxytryptamine receptors (5-HT 2C and 5-HT 3 ), and hypothalamic feeding-related peptides were measured by immunohistochemistry staining, enzyme-linked immunosorbent assay, and real-time PCR assay.Key results: Cisplatin administration caused marked decrease in appetite and body weight, promoted adipose and fat tissue atrophy, and delayed gastric emptying and gastric distension, and D-methionine preadministration prior to cisplatin administration significantly ameliorated these side effects. Besides, cisplatin induced an evident increase in serum ghrelin level, TPH1 activity, and 5-HT 3 receptor expression in the intestine and decreased plasma leptin levels and gastric ghrelin mRNA gene expression levels. D-methionine supplementation recovered these changes. The expression of orexigenic neuropeptide Y/ agouti-related peptide and anorexigenic cocaine-and amphetamine-regulated transcript proopiomelanocortin neurons were altered by D-methionine supplementation in cisplatininduced anorexia rats. Conclusions and inferences: D-methionine supplementation prevents cisplatin-in-duced anorexia and dyspepsia syndrome possibly by attenuating intestinal tryptophan hydroxylase 1 activity and increasing plasma leptin concentration. Therefore, D-methionine can be used as an adjuvant therapy for treating cisplatin-induced adverse effects.

show abstract

Role of eating disorders-related polymorphisms in obesity pathophysiology

Cited by 19 publications

References 115 publications

DRD2 and BDNF Polymorphisms Are Associated With Binge Eating Disorder (BED) in Patients With Weight Regain After Bariatric Surgery

DRD2 and BDNF Polymorphisms Are Associated With Binge Eating Disorder (BED) in Patients With Weight Regain After Bariatric Surgery

Is weight regain after bariatric surgery associated with psychiatric comorbidity? A systematic review and meta‐analysis

D‐methionine improves cisplatin‐induced anorexia and dyspepsia syndrome by attenuating intestinal tryptophan hydroxylase 1 activity and increasing plasma leptin concentration

Contact Info

Product

Resources

About